Agenus Inc. (AGEN) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to Agenis, Inc.' 's investor briefing call. Currently, all participants are in a listen-only mode. A question-and-answer session will follow the formal remarks. As a reminder, this conference is being recorded. I will now turn the call over to Zach Arman, head of investor relations. Thank you, operator. Welcome to Agenis' investor briefing call. Earlier today, we issued a press release announcing a strategic collaboration between Agenis and Zytus Life Sciences, which we are here to review in more detail with you today. A copy of the press release is available on our website at www.investors.agenisbio.com. Before we begin, I'd like to remind everyone that today's discussion will include forward-looking statements. These statements are subject to risks and uncertainties, which may cause actual results to differ materially from expectations. Please refer to our SEC filings for further detail. Joining me today are Garrel Arman, Chairman and CEO, and Dr. Stephen O'Day, Chief Medical Officer. I'll now turn the call over to Garrel Arman. Thank you, Zach, and good afternoon, everyone. Thank you for joining us. On today's call, we will be discussing an exciting new partnership between Agenis Enzytis. It's an exciting opportunity for both companies and for trade between two great nations, the world's oldest democracy and the world's largest democracy. But before I get into the details, I want to start with why this is so important. As you've been hearing lately, colorectal cancer is on the rise, particularly among the younger people under the age of 50. Colorectal cancer, which is known as CRC, incidences have doubled in the US adults under 55 from 1995 to present. By 2030, colorectal cancer is projected to become the leading cause of cancer-related...